Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

Caught Red-Handed

Cycling Cardiomyocytes

Olaf Bergmann, Thomas Braun
Download PDF
https://doi.org/10.1161/CIRCRESAHA.115.307936
Circulation Research. 2016;118:3-5
Originally published January 7, 2016
Olaf Bergmann
From the Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (O.B.); and Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (T.B.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Braun
From the Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (O.B.); and Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (T.B.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading
  • Editorials
  • cell cycle progression, mouse
  • cyclin A2
  • myocardium
  • myocytes, cardiac
  • stem cells

During the past couple of years, overwhelming evidence has accumulated that the myocardium in adult mammals including humans undergoes significant renewal.1,2 The underlying homeostatic renewal process enables the heart to partially replace essential building blocks during a lifetime but is not sufficient to cope with the increased loss of cardiomyocytes under acute or chronic pathological conditions. Although good reasons might exist why nature has restricted replacement of cardiomyocytes in adult mammals, enhancement of the physiological renewal rate by therapeutic interventions might provide means to unearth hidden regenerative capacities and restore lost cardiac functions.

Article, see p 20

At present, no consensus exists about the source of cells enabling homeostatic renewal of the myocardium in adult mammals. New cardiomyocytes might originate from rare divisions of existing cardiomyocytes, probably after moderate or extensive cardiomyocyte dedifferentiation, from putative cardiac stem cells, or from a combination of both. Several attempts have been made in the past to monitor cardiomyocyte division in the developing and adult myocardium, clearly defining the major phases of cardiomyocytes proliferation.3 However, reliable detection of rare cell cycling events in adult cardiomyocytes proved to be difficult, mostly because of the tightly packed arrangement of multiple cell types in the myocardium4 and the abundance of noncardiomyocytes, which constitute 60% of all cell nuclei in the neonatal mouse heart and ≈70% in young adult mice.5 Pioneering research from Loren Field’s group has used genetic labeling of cardiomyocytes in mice using an myosin heavy chain-nuclear localized p-galactosidase reporter transgene in combination with tritiated thymidine incorporation to overcome this problem,3 whereas others have used antibodies against pericentriolar material 1 as an accurate marker to label human and murine cardiomyocyte nuclei.6 However, such approaches are either cumbersome and time-consuming or rely on the use of multiple antibodies. Therefore, other researchers have integrated different read-outs (ie, identification of a specific cell type and monitoring of cell cycle activity) into a single system by using cardiomyocyte-specific promoters driving the expression of cell cycle markers, which provided a detailed map of cell cycle dynamics during development in living cardiomyocytes.5,7

Hirai at al8 have now come up with another simple and robust system to monitor S- to M-phase cell cycle activity in murine cells. The approach relies on the conditional activation of a cyclinA2–enhanced green fluorescent protein (eGFP) fusion gene by expression of Cre-recombinase. In their study, Hirai at al8 have used a Protamine-Cre line to activate the cyclinA2–eGFP fusion gene in the germ line, which allows assessment of cell cycle activity in all cells. In addition, the authors have taken advantage of a cardiac myocyte–specific troponin T-Cre recombinase (TnT-Cre) transgene to specifically activate the reporter gene in cardiomyocytes. The new tool was validated by comparing cell cycle–specific expression of eGFP to incorporation of the thymidine analogue 5-ethynyl-2´-deoxyuridine (EdU) and appearance of the M-phase marker phosphohistone H3, which mark S and M phase, respectively (Figure [A]). Importantly, cyclinA2–eGFP expression was completely lost within 6 to 12 hours after synchronized embryonic fibroblasts were forced into cell cycle arrest (G0) by serum starvation. This experiment convincingly demonstrated that the cyclinA2–eGFP fusion protein is rapidly degraded during M phase and therefore not carried over from one cell cycle to the next. In the TnT-Cre×cyclinA2–eGFP transgenic mouse ≈80% of all cyclinA2–eGFP positive cardiomyocytes incorporated EdU when a single EdU injection was given to the animals 2 or 4 hours before the analysis. This finding was expected because EdU is only incorporated during S phase, whereas cyclinA2–eGFP is already expressed at mid-G1. Analysis of the mitotic activity of cardiomyocytes at different developmental stages with the new technique confirmed previously published results reporting a gradual decrease of cardiomyocyte proliferation with progressive development including a major decline of mitotic activity in the early postnatal period. Furthermore, the authors made several new observations. First (and probably most important), Hirai at al8 did not find evidence for a proliferative burst of ventricular cardiomyocytes at postnatal day 15, which was claimed recently in a hotly debated publication in Cell by Naqvi et al9 to establish the final cardiomyocyte number in mouse hearts. Instead, Hirai at al8 detected a further gradual and steady decline of mitotic activity from postnatal day 14 to 20, which eventually resulted in a nearly complete cessation of cell cycle activity in the first 3 weeks after birth. Recently, Alkass et al6 and Soonpaa et al10 published similar results using the above-mentioned pericentriolar material 1/5-bromo-2´-deoxyuridine (BrdU) and myosin heavy chain-nuclear localized p-galactosidase reporter/BrdU double-labeling approach, respectively. Hence, it seems safe to say that a burst of preadolescent cell cycle activity is not required for normal cardiac development. Second, Hirai at al8 disclosed a previously unrecognized lower rate of cardiomyocyte cell cycle activity after birth at P0 and P1 in the right when compared with the left ventricle. The early cell cycle exit in the right ventricle might, at least in part, contribute to differences in ventricular wall thickness that emerge during postnatal development. However, additional studies are clearly required to validate this finding and explore its significance.

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

Schematic comparison of different cardiomyocyte cell cycle reporter systems in mice. A, Cell cycle–specific degradation of the cyclinA2–enhanced green fluorescent protein (eGFP) fusion protein (green) allows labeling of cardiomyocyte nuclei from S to M phase. Expression of the cyclinA2–eGFP fusion protein starts in mid-G1 phase, peaks in S phase, and fades out in mitosis. Expression in cardiomyocytes is activated by troponin T-Cre recombinase (TnT-Cre). B, Combination of CAG–Anillin–eGFP (green) and α-myosin heavy chain promoter-dependent hH2B-mCherry expression (red) allows identification of cardiomyocytes in G0, G1 to G2, karyokinesis, and cytokinesis. Anillin is located in the nucleus during G1, S, and G2 phase, in the cytoplasm in early M phase, and in the contractile ring in cytokinesis. C, The multicolored fluorescent ubiquitination-based cell cycle indicator (FUCCI) system allows identification of cells in G1 (red) and in S/G2/M (green) phases. FUCCI exploits the cell cycle–dependent ubiquitination and degradation of Cdt1-Kusabira Orange and Geminin-Azami Green. Cdt1-Kusabira Orange levels are highest in G1, whereas Geminin-Azami Green levels are highest during the S/G2/M phases. Cre-dependent activation of FUCCI in the Rosa26 locus generates cell type specificity.

The new tool developed by Hirai at al8 provides many advantages when compared with traditional approaches such as ease of use, dependence on a single fluorescence marker, high reliability, and superior sensitivity when compared with EdU incorporation. In addition, potential adverse effects of BrdU or EdU incorporation can be ruled out and noise generated by incorporation of labeled nucleosides during DNA repair. On the contrary, a couple of limitations is evident, which leaves room for further improvement. cyclinA2 expression marks the S to M phases of cell cycle but does not necessarily indicate cytokinesis. In fact, Hirai at al8 observed cyclinA2–eGFP activity during cell cycle events in the early postnatal period, which preceded binucleation. In other words, the cyclinA2–eGFP reporter will label cardiomyocytes that undergo binucleation and most likely also endoreduplication but not necessarily commit to cytokinesis. Visualization of midbody formation in cardiomyocytes using eGFP fused to the scaffolding protein anillin as recently described by Hesse et al11 might provide a more reliable approach to detect dividing cardiomyocytes although Hesse et al11 used an ubiquitous promoter to drive expression of the EGFP–anillin fusion and did not attempt to restrict the expression to the cardiomyogenic lineage. However, combination of the CAG–anillin:eGFP line with mice that express a fusion protein of human histone 2B and the red fluorescence protein mCherry under the control of the α-myosin heavy chain promoter allows trustworthy detection of dividing cardiomyocytes (Figure [B]).12

Activation of the cyclinA2–eGFP reporter relies on the cell type–specific expression of Cre-recombinase, which makes it difficult to combine the technique with other Cre-recombinase–based labeling approaches. For example, Kimura et al13 have recently devised a clever system for fate mapping of hypoxic cardiomyocytes, which are present at low numbers in the adult heart but contribute widely to formation of new cardiomyocytes. Obviously, it would be highly useful to label hypoxic cardiomyocytes and simultaneously monitor cell cycle activity in real time. The use of different recombinases like Flp and Cre that do not interfere with each other might overcome such compatibility issues and combine the benefits of both approaches. Finally, the cyclinA2–eGFP reporter described by Hirai at al8 does not allow live cell tracing and visualization of different phases of the cardiomyocyte cell cycle, which was possible with a recently described multicolored cell cycle fluorescent ubiquitination-based cell cycle indicator reporter.7 Fluorescent ubiquitination-based cell cycle indicator was first described in 2008 by Sakaue-Sawano et al14 and exploits the regulation of cell cycle–dependent ubiquitination to effectively label individual cell nuclei in G1 phase in red, and those in S/G2/M phases in green (Figure [C]). On the contrary, the current fluorescent ubiquitination-based cell cycle indicator system is also not without disadvantages, namely, the low fluorescence intensities of green/red reporters in different cell types, which makes live cell imaging of rarely dividing cardiomyocytes a challenge. A careful selection of the reporter or assay systems will always be necessary to fit the specific experimental needs and the underlying scientific question. Time will tell whether future cell cycle reporters can combine all features of the above-described systems and qualify as a Jack-of-all-trades.

Sources of Funding

Dr Braun was supported by the Max-Planck-Society, the Deutsche Forschungsgemeinschaft (Excellence Cluster Cardio-Pulmonary System, and Sonderforschungsbereich TR81), the Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz Center for Cell and Gene Therapy, and the German Center for Cardiovascular Research. Dr Bergmann was supported by the Karolinska Institutet, the Swedish Research Council, the Ragnar Söderberg Foundation, and the Jeansson Foundations.

Disclosures

None.

Footnotes

  • The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

  • © 2016 American Heart Association, Inc.

References

  1. 1.↵
    1. Bergmann O,
    2. Bhardwaj RD,
    3. Bernard S,
    4. Zdunek S,
    5. Barnabé-Heider F,
    6. Walsh S,
    7. Zupicich J,
    8. Alkass K,
    9. Buchholz BA,
    10. Druid H,
    11. Jovinge S,
    12. Frisén J
    . Evidence for cardiomyocyte renewal in humans. Science. 2009;324:98–102. doi: 10.1126/science.1164680.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Bergmann O,
    2. Zdunek S,
    3. Felker A,
    4. et al
    . Dynamics of cell generation and turnover in the human heart. Cell. 2015;161:1566–1575. doi: 10.1016/j.cell.2015.05.026.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Soonpaa MH,
    2. Kim KK,
    3. Pajak L,
    4. Franklin M,
    5. Field LJ
    . Cardiomyocyte DNA synthesis and binucleation during murine development. Am J Physiol. 1996;271:H2183–H2189.
    OpenUrl
  4. 4.↵
    1. Soonpaa MH,
    2. Rubart M,
    3. Field LJ
    . Challenges measuring cardiomyocyte renewal. Biochim Biophys Acta. 2013;1833:799–803. doi: 10.1016/j.bbamcr.2012.10.029.
    OpenUrlCrossRef
  5. 5.↵
    1. Raulf A,
    2. Horder H,
    3. Tarnawski L,
    4. Geisen C,
    5. Ottersbach A,
    6. Röll W,
    7. Jovinge S,
    8. Fleischmann BK,
    9. Hesse M
    . Transgenic systems for unequivocal identification of cardiac myocyte nuclei and analysis of cardiomyocyte cell cycle status. Basic Res Cardiol. 2015;110:33. doi: 10.1007/s00395-015-0489-2.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Alkass K,
    2. Panula J,
    3. Westman M,
    4. Wu TD,
    5. Guerquin-Kern JL,
    6. Bergmann O
    . No Evidence for Cardiomyocyte Number Expansion in Preadolescent Mice. Cell. 2015;163:1026–1036. doi: 10.1016/j.cell.2015.10.035.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Hashimoto H,
    2. Yuasa S,
    3. Tabata H,
    4. et al
    . Time-lapse imaging of cell cycle dynamics during development in living cardiomyocyte. J Mol Cell Cardiol. 2014;72:241–249. doi: 10.1016/j.yjmcc.2014.03.020.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Hirai M,
    2. Chen J,
    3. Evans SM
    . Tissue-specific cell cycle indicator reveals unexpected findings for cardiac myocyte proliferation. Circ Res. 2016;118:20–28. doi: 10.1161/CIRCRESAHA.115.307697.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Naqvi N,
    2. Li M,
    3. Calvert JW,
    4. et al
    . A proliferative burst during preadolescence establishes the final cardiomyocyte number. Cell. 2014;157:795–807. doi: 10.1016/j.cell.2014.03.035.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Soonpaa MH,
    2. Zebrowski DC,
    3. Platt C,
    4. Rosenzweig A,
    5. Engel FB,
    6. Field LJ
    . Cardiomyocyte cell-cycle activity during preadolescence. Cell. 2015;163:781–782. doi: 10.1016/j.cell.2015.10.037.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Hesse M,
    2. Raulf A,
    3. Pilz GA,
    4. et al
    . Direct visualization of cell division using high-resolution imaging of M-phase of the cell cycle. Nat Commun. 2012;3:1076. doi: 10.1038/ncomms2089.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Raulf A,
    2. Horder H,
    3. Tarnawski L,
    4. Geisen C,
    5. Ottersbach A,
    6. Röll W,
    7. Jovinge S,
    8. Fleischmann BK,
    9. Hesse M
    . Transgenic systems for unequivocal identification of cardiac myocyte nuclei and analysis of cardiomyocyte cell cycle status. Basic Res Cardiol. 2015;110:489.
    OpenUrl
  13. 13.↵
    1. Kimura W,
    2. Xiao F,
    3. Canseco DC,
    4. et al
    . Hypoxia fate mapping identifies cycling cardiomyocytes in the adult heart. Nature. 2015;523:226–230. doi: 10.1038/nature14582.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Sakaue-Sawano A,
    2. Kurokawa H,
    3. Morimura T,
    4. Hanyu A,
    5. Hama H,
    6. Osawa H,
    7. Kashiwagi S,
    8. Fukami K,
    9. Miyata T,
    10. Miyoshi H,
    11. Imamura T,
    12. Ogawa M,
    13. Masai H,
    14. Miyawaki A
    . Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell. 2008;132:487–498. doi: 10.1016/j.cell.2007.12.033.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
January 8, 2016, Volume 118, Issue 1
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Caught Red-Handed
    Olaf Bergmann and Thomas Braun
    Circulation Research. 2016;118:3-5, originally published January 7, 2016
    https://doi.org/10.1161/CIRCRESAHA.115.307936

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Caught Red-Handed
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Caught Red-Handed
    Olaf Bergmann and Thomas Braun
    Circulation Research. 2016;118:3-5, originally published January 7, 2016
    https://doi.org/10.1161/CIRCRESAHA.115.307936
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Myocardial Biology
    • Myocardial Regeneration
    • Developmental Biology

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured